Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
Ji Eun Shin, Soo‐Hyun Kim, Mingyu Kong, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 18

Showing 18 citing articles:

Multi-omics advances for molecular characterization, precision medicine, and prognostic implications in leukemia
Shangyu Hou, Junya Liu, Yinghui Zhu
Cell investigation. (2025) Vol. 1, Iss. 1, pp. 100007-100007
Open Access | Times Cited: 2
Noncanonical role of Golgi-associated macrophage TAZ in chronic inflammation and tumorigenesis
S. Park, Sungeun Ju, Jae Hoon Lee, et al.
Science Advances (2025) Vol. 11, Iss. 4
Open Access | Times Cited: 1
Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth
Weidong Peng, Haojie Zhang, Mingwei Yin, et al.
Oncogenesis (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Luteolin Mitigates Acute Lung Injury Through Immune Modulation and Antinecroptosis Effects by Targeting the BTK and FLT3 Signaling Pathways
Zhixing Cao, Huanan Rao, Wenya Yang, et al.
Journal of Agricultural and Food Chemistry (2025) Vol. 73, Iss. 9, pp. 5180-5193
Closed Access
Repositioning of FDA-approved anti-cancer drugs for fatal blast crisis CML by integrated high-throughput genomic and artificial intelligence-based drug discovery analyses of pan-leukemic genetic abnormalities: Implications in post-COVID-19 era
Zafar Iqbal, Nawaf Alanazi, Sarah AlMukhaylid, et al.
Research Square (Research Square) (2025)
Closed Access
CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies
Mengting Qin, Jianhua Ren, Xiaodong Chen, et al.
Theranostics (2025) Vol. 15, Iss. 8, pp. 3589-3609
Open Access
A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia
Valeria Bica, Veronica Venafra, Giorgia Massacci, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia
Hyun-Jin Kwon, Ji Eun Shin, Amir Khan, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Clinical Validation Of ANKRD36 Mutations As A Novel Biomarker For Monitoring Early Progression and Timely Clinical Interventions In Blast Crisis CML
Nawaf Alanazi, Muhammad Absar, Abdulaziz Siyal, et al.
(2024)
Open Access | Times Cited: 1
Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid Leukemia
Zafar Iqbal, Muhammad Absar, Tanveer Akhtar, et al.
(2024)
Open Access | Times Cited: 1
Emerging paradigms in cancer cell plasticity
Hyunbin D. Huh, Hyun Woo Park
BMB Reports (2024) Vol. 57, Iss. 6, pp. 273-280
Open Access | Times Cited: 1
Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case–Control Study
Nawaf Alanazi, Abdulaziz Siyal, Sulman Basit, et al.
Hematology Reports (2024) Vol. 16, Iss. 3, pp. 465-478
Open Access | Times Cited: 1
Combined Inhibition of PI3K and STAT3 Signaling is Effective in Bladder Cancer Treatment
Yang Li, Weidong Peng, Haojie Zhang, et al.
Research Square (Research Square) (2024)
Open Access
Adherent-suspension plasticity promotes the dissemination and colonization of circulating tumor cells
Hyunbin D. Huh, Yujin Sub, Jee Hung Kim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Next-Generation DNA Sequencing Identifies Mutated FANCD2 Gene as a Novel Biomarker for Monitoring Early Disease Progression and Timely Therapeutic Interventions in Advanced Phase Chronic Myeloid Leukemia Patients
Nawaf Alanzazi, Abdulaziz Siyal, Muhammad Absar, et al.
(2023)
Open Access | Times Cited: 1
Next-generation DNA sequencing identifies mutated FANCD2 Gene as a novel Biomarker for monitoring early disease progression and timely therapeutic interventions in advanced phase Chronic Myeloid Leukemia patients
Nawaf Alanazi, Abdulaziz Siyal, Muhammad Absar, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Investigations on Clinical Validation of mutated ANKRD36 as a Novel Molecular Biomarker for Monitoring Early Progression and Timely Therapeutic Interventions in Blast Crisis CML
Nawaf Alanazi, Abdulaziz Siyal, Muhammad Absar, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML
Muhammad Absar, Nawaf Alanazi, Abdulaziz Siyal, et al.
(2022), pp. 311-320
Open Access
Page 1

Scroll to top